Neurocrine Biosciences, Inc. (NBIX) Social Stream
NEUROCRINE BIOSCIENCES INC (NBIX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering NEUROCRINE BIOSCIENCES INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-03 | 20 | $150 | $100 | $123.5 | $108.8 | 13.51% |
| 2021-11-17 | 20 | $150 | $100 | $123.222 | $108.8 | 13.26% |
| 2021-11-19 | 20 | $150 | $76 | $120.736 | $108.8 | 10.97% |
| 2021-12-07 | 21 | $150 | $76 | $120.736 | $108.8 | 10.97% |
| 2022-01-07 | 22 | $154 | $76 | $122 | $108.8 | 12.13% |
| 2022-01-10 | 22 | $154 | $76 | $121.789 | $108.8 | 11.94% |
| 2022-01-18 | 22 | $154 | $76 | $120.263 | $108.8 | 10.54% |
| 2022-01-26 | 22 | $154 | $76 | $119.052 | $108.8 | 9.42% |
| 2022-01-30 | 22 | $154 | $76 | $117.157 | $108.8 | 7.68% |
| 2022-01-31 | 22 | $154 | $76 | $116.736 | $108.8 | 7.29% |
| 2022-02-14 | 21 | $154 | $76 | $116.473 | $108.8 | 7.05% |
| 2022-02-16 | 21 | $150 | $76 | $116.473 | $108.8 | 7.05% |
| 2022-02-25 | 21 | $150 | $76 | $115.65 | $108.8 | 6.3% |
| 2022-03-03 | 21 | $150 | $76 | $114.6 | $108.8 | 5.33% |
| 2022-04-12 | 20 | $150 | $76 | $114.65 | $108.8 | 5.38% |
| 2022-04-21 | 19 | $150 | $76 | $114.55 | $108.8 | 5.28% |
| 2022-05-04 | 20 | $150 | $76 | $114.8 | $108.8 | 5.51% |
| 2022-05-05 | 20 | $150 | $76 | $114.6 | $108.8 | 5.33% |
| 2022-05-06 | 19 | $150 | $76 | $114.4 | $108.8 | 5.15% |
| 2022-05-10 | 19 | $150 | $76 | $114.368 | $108.8 | 5.12% |
| 2022-06-02 | 19 | $150 | $76 | $114.315 | $108.8 | 5.07% |
| 2022-06-06 | 19 | $150 | $76 | $113.578 | $108.8 | 4.39% |
| 2022-08-01 | 19 | $150 | $76 | $113.736 | $108.8 | 4.54% |
| 2022-08-05 | 20 | $150 | $76 | $114.052 | $108.8 | 4.83% |
| 2022-08-13 | 20 | $150 | $76 | $114.5 | $108.8 | 5.24% |
| 2022-08-18 | 20 | $150 | $76 | $114.9 | $108.8 | 5.61% |
| 2022-09-21 | 20 | $150 | $76 | $115.55 | $108.8 | 6.2% |
| 2022-09-26 | 20 | $150 | $76 | $115.285 | $108.8 | 5.96% |
| 2022-10-11 | 21 | $150 | $76 | $116.227 | $108.8 | 6.83% |
| 2022-10-13 | 21 | $150 | $76 | $116.818 | $108.8 | 7.37% |
| 2022-10-20 | 22 | $150 | $76 | $116.304 | $108.8 | 6.9% |
| 2022-10-21 | 22 | $150 | $76 | $116.347 | $108.8 | 6.94% |
| 2022-10-24 | 21 | $150 | $76 | $116.608 | $108.8 | 7.18% |
| 2022-11-02 | 21 | $150 | $91 | $121.478 | $108.8 | 11.65% |
| 2022-11-03 | 21 | $150 | $101 | $125.391 | $108.8 | 15.25% |
| 2022-11-14 | 22 | $150 | $101 | $126.043 | $108.8 | 15.85% |
| 2023-01-17 | 21 | $150 | $101 | $126.043 | $108.8 | 15.85% |
| 2023-01-23 | 21 | $150 | $101 | $126.13 | $108.8 | 15.93% |
The Trend in the Analyst Price Target
NBIX's average price target has moved down $1.92 over the prior 22 months.
NBIX reports an average of 22.75% for its upside potential over the past 52 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-14 | 21 | 150 | 76 | 116.421 | 86.52 | 34.56% |
| 2022-02-16 | 21 | 150 | 76 | 116.473 | 85.87 | 35.64% |
| 2022-03-03 | 20 | 150 | 76 | 114.600 | 87.62 | 30.79% |
| 2022-05-06 | 19 | 150 | 76 | 114.368 | 79.55 | 43.77% |
| 2022-09-10 | 20 | 150 | 76 | 115.550 | 106.51 | 8.49% |
NBIX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.71 | 13 | 1 | 7 | 0 | 0 | 21 |
The Trend in the Broker Recommendations
Over the past 52 weeks, NBIX's average broker recommendation rating improved by 0.06.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, NEUROCRINE BIOSCIENCES INC's number of analysts covering the stock is higher than 4672.27% of them.
- In terms of how NEUROCRINE BIOSCIENCES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 4306.88% of that group.
- In the context of Pharmaceutical Products stocks, NEUROCRINE BIOSCIENCES INC's upside potential (average analyst target price relative to current price) is greater than 620.05% of them.
- NBIX has a lower variance in analysts' estimates than -3273.03% of stocks in the large market cap category.
In the Pharmaceutical Products industry, GILD, BIIB, and TECH are the three stocks most similar to NEUROCRINE BIOSCIENCES INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding NBIX using the data that counts. Try POWR Ratings for free.